Tempest Secures Lifeline to Fund Promising CAR-T Cancer Therapy

BRISBANE, CA – March 23, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) today announced a private placement to raise up to $6 million, a critical financial maneuver designed to fuel its ambitious pipeline of advanced cancer therapies. The deal, however, was met with initial investor apprehension, highlighting the precarious balance the clinical-stage biotechnology firm must strike between scientific innovation and financial survival.

The company entered into definitive agreements for an immediate infusion of approximately $2 million in gross proceeds, with the potential for an additional $4 million through the exercise of accompanying warrants. The funds are earmarked for working capital and general corporate purposes, effectively providing a much-needed lifeline to advance its cutting-edge CAR-T cell therapy programs.

Despite the positive long-term implications of the funding, the market's immediate reaction underscored the challenges faced by the company. Tempest's stock saw a significant pre-market dip of nearly 12% following the announcement, reflecting investor concerns over share dilution and the company's underlying financial health.

A Lifeline Amid Financial Headwinds

The capital raise comes at a pivotal moment for Tempest. Recent financial filings paint a picture of a company with a high cash burn rate, a common reality in the capital-intensive world of biotech research and development. The company’s cash and cash equivalents had fallen from $30.3 million at the end of 2024 to just $7.5 million by the end of the third quarter of 2025. While its liquid assets still exceed short-term obligations, its financial health has been rated as "WEAK" by some market data providers, with a negative free cash flow of over $33 million in the last twelve months.

This context makes the new financing not just strategic, but essential. The initial $2 million provides immediate liquidity to sustain operations. According to one financial commentary, the transaction is a "small but structured capital raise that modestly strengthens liquidity." While it extends the company's operational runway, the amount is considered modest for a firm developing CAR-T therapies, one of the most expensive and complex frontiers in modern medicine. This suggests that while the deal provides breathing room, Tempest will likely need to pursue additional funding or strategic partnerships to see its most promising candidates through late-stage clinical trials and to commercialization.

The Price of Progress: Dissecting the Deal

The structure of the financing, managed by H.C. Wainwright & Co., involves the sale of 925,927 shares of common stock (or pre-funded warrants) at a combined price of $2.16 per share and accompanying warrants. This price represents a slight discount to the stock's closing price of $2.29 on the last trading day before the announcement, a common practice to attract investors in such placements. The company's stock has faced significant headwinds, plunging over 78% in the past year, which adds pressure to its fundraising efforts.

The deal includes both series A warrants, expiring in five years, and short-term series B warrants, expiring in twenty-four months, both with an exercise price of $2.16. This structure provides Tempest with potential future funding if the warrants are exercised, but it also creates a "warrant overhang." This can place downward pressure on the stock price, as the market anticipates the potential for future share dilution when and if these warrants are converted into common stock.

Significantly, the list of participants includes not only institutional investors but also Factor Bioscience Inc., identified as a "Strategic Investor." This is a crucial vote of confidence. In November 2025, Tempest acquired its dual-targeting CAR-T programs from Factor Bioscience. Factor's decision to participate in this financing signals its continued belief in the potential of the assets it sold to Tempest and a strong strategic alignment between the two companies.

Fueling the Fight Against Cancer

Beyond the financial complexities, the new capital is intended to propel a pipeline that has shown remarkable promise. The primary focus is on Tempest's portfolio of Chimeric Antigen Receptor T-cell (CAR-T) therapies, a revolutionary approach that engineers a patient's own immune cells to fight cancer.

The standout candidate is TPST-2003, a dual-targeting CAR-T therapy aimed at both CD19 and BCMA proteins, which are found on cancerous cells in various blood cancers. In an ongoing Phase 1 trial in China, the therapy has demonstrated extraordinary results. Data from the REDEEM-1 trial showed a 100% overall response rate among six evaluable patients, with all six achieving a complete response. This stellar efficacy, coupled with a manageable safety profile, has positioned TPST-2003 as a potential best-in-class treatment.

Tempest is employing a capital-efficient strategy by leveraging a partner to fund the development in China, allowing it to gather pivotal data while conserving its own resources. With the new funding, the company is preparing to file an Investigational New Drug (IND) application in the U.S. by the end of 2026, a major step toward bringing the therapy to American patients.

The funding will also support preclinical work on TPST-4003, a next-generation in vivo CAR-T program designed to deliver the therapy directly within the body, potentially eliminating the complex and costly ex vivo manufacturing process required for current CAR-T treatments.

Navigating a Competitive and Costly Landscape

Tempest is operating in one of the hottest, most competitive, and most expensive sectors of the biopharmaceutical industry. The global CAR-T therapy market is valued at nearly $5 billion and is projected to grow exponentially, dominated by giants like Novartis, Gilead Sciences, and Bristol Myers Squibb. For a small company like Tempest, innovation is the key to differentiation.

Its focus on dual-targeting CARs and in vivo delivery systems places it at the forefront of next-generation research aimed at overcoming the limitations of current therapies. However, the high costs of manufacturing, clinical trials, and navigating the regulatory landscape create a constant need for capital. This private placement, while dilutive, is a necessary step for a small player to continue its high-stakes journey. The company's ability to advance its scientifically promising assets now depends on its prudent management of this new, critical injection of funds.